BioNTech to acquire mRNA drugmaker CureVac for up to $1.25bn
The German biotech firm plans to integrate CureVac's research and manufacturing site in Tübingen into its operations, and its expertise in the research, development, and marketing of mRNA-based cancer immunotherapy.

Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry